Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Emily K Kleczko"'
Autor:
Emily K. Kleczko, Trista K. Hinz, Teresa T. Nguyen, Natalia J. Gurule, Andre Navarro, Anh T. Le, Amber M. Johnson, Jeff Kwak, Diana I. Polhac, Eric T. Clambey, Mary Weiser-Evans, Daniel T. Merrick, Michael C. Yang, Tejas Patil, Erin L. Schenk, Lynn E. Heasley, Raphael A. Nemenoff
Publikováno v:
npj Precision Oncology, Vol 7, Iss 1, Pp 1-11 (2023)
Abstract Lung cancers bearing oncogenic EML4-ALK fusions respond to targeted tyrosine kinase inhibitors (TKIs; e.g., alectinib), with variation in the degree of shrinkage and duration of treatment (DOT). However, factors that control this response ar
Externí odkaz:
https://doaj.org/article/8192c462eff74d50be9a1f7314bb046e
Autor:
Emily K. Kleczko, Dustin T. Nguyen, Kenneth H. Marsh, Colin D. Bauer, Amy S. Li, Marie-Louise T. Monaghan, Michael D. Berger, Seth B. Furgeson, Berenice Y. Gitomer, Michel B. Chonchol, Eric T. Clambey, Kurt A. Zimmerman, Raphael A. Nemenoff, Katharina Hopp
Publikováno v:
JCI Insight, Vol 8, Iss 12 (2023)
Innate and adaptive immune cells modulate the severity of autosomal dominant polycystic kidney disease (ADPKD), a common kidney disease with inadequate treatment options. ADPKD has parallels with cancer, in which immune checkpoint inhibitors have bee
Externí odkaz:
https://doaj.org/article/db0e24d1120a4e91b18a5137cdd01738
Autor:
Daniel J. Sisler, Trista K. Hinz, Anh T. Le, Emily K. Kleczko, Raphael A. Nemenoff, Lynn E. Heasley
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
IntroductionThe KRAS(G12C) mutation is the most common genetic mutation in North American lung adenocarcinoma patients. Recently, direct inhibitors of the KRASG12C protein have been developed and demonstrate clinical response rates of 37-43%. Importa
Externí odkaz:
https://doaj.org/article/cb227c2f9f5440f7a6ba0d3df80f32ec
Autor:
Dustin T. Nguyen, Emily K. Kleczko, Nidhi Dwivedi, Marie-Louise T. Monaghan, Berenice Y. Gitomer, Michel B. Chonchol, Eric T. Clambey, Raphael A. Nemenoff, Jelena Klawitter, Katharina Hopp
Publikováno v:
JCI Insight, Vol 8, Iss 1 (2023)
Autosomal dominant polycystic kidney disease (ADPKD), the most common monogenic nephropathy, is characterized by phenotypic variability that exceeds genic effects. Dysregulated metabolism and immune cell function are key disease modifiers. The trypto
Externí odkaz:
https://doaj.org/article/309833323f31402ebb2adcd39a55bdfc
Autor:
Emily K. Kleczko, Joanna M. Poczobutt, Andre C. Navarro, Jennifer Laskowski, Amber M. Johnson, Sean P. Korpela, Natalia J. Gurule, Lynn E. Heasley, Katharina Hopp, Mary C.M. Weiser-Evans, Elizabeth B. Gottlin, Ryan T. Bushey, Michael J. Campa, Edward F. Patz, Joshua M. Thurman, Raphael A. Nemenoff
Publikováno v:
Frontiers in Oncology, Vol 12 (2023)
IntroductionIn vivo, cancer cells respond to signals from the tumor microenvironment resulting in changes in expression of proteins that promote tumor progression and suppress anti-tumor immunity. This study employed an orthotopic immunocompetent mod
Externí odkaz:
https://doaj.org/article/eb6828e59da5493f9cf674acdf9e3ecc
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Background Resistance to therapy is a major problem in treating head and neck squamous cell carcinomas (HNSCC). Complement system inhibition has been shown to reduce tumor growth, metastasis, and therapeutic resistance in other tumor models, but has
Externí odkaz:
https://doaj.org/article/7b398750e9264d619aeb8badf15634ac
Publikováno v:
Frontiers in Pharmacology, Vol 11 (2020)
Eicosanoids represent a family of active biolipids derived from arachidonic acid primarily through the action of cytosolic phospholipase A2-α. Three major downstream pathways have been defined: the cyclooxygenase (COX) pathway which produces prostag
Externí odkaz:
https://doaj.org/article/eccb824a70db474fae7ac99f2f8b1c98
Autor:
Emily K. Kleczko, Lynn E. Heasley
Publikováno v:
Molecular Cancer, Vol 17, Iss 1, Pp 1-11 (2018)
Abstract Receptor tyrosine kinase (RTK) pathways serve as frequent oncogene drivers in solid cancers and small molecule and antibody-based inhibitors have been developed as targeted therapeutics for many of these oncogenic RTKs. In general, these dru
Externí odkaz:
https://doaj.org/article/9e6e31b06ca04d5493b0604cea728cd9
Publikováno v:
Frontiers in Immunology, Vol 10 (2019)
Lung cancer is the leading cause of cancer death in men and women. Lung adenocarcinoma (LUAD), represents approximately 40% of all lung cancer cases. Advances in recent years, such as the identification of oncogenes and the use of immunotherapies, ha
Externí odkaz:
https://doaj.org/article/c4318923130649ba836db0e7bf51221a
Autor:
Lynn E. Heasley, Sven Perner, Joseph M. Gozgit, Arne Warth, Hans Hoffmann, Raphael A. Nemenoff, Mary C. Weiser-Evans, Diana Boehm, Emily K. Kleczko, Kyle A. Olszewski, Anne von Mässenhausen, Trista K. Hinz, Lindsay A. Marek
Figure S1. Fluorescence in situ hybridization (FISH) analysis of FGFR1 gene copy number status in mesothelioma cell lines. Figure S2. Bioluminescence imaging of orthotopically implanted H226 tumors treated with or without ponatinib. Supplementary Tab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72aaca3af0c29d5b3500aecdfa0171b1
https://doi.org/10.1158/1541-7786.22514688.v1
https://doi.org/10.1158/1541-7786.22514688.v1
